Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-11 inhibit the growth of androgen-independent PC- 3 prostate cancer in nude mice

Prostate

Volumn 32, Issue 3, 1997, Pages 164-172

  Jungwirth, Andreas ^a,c   Galvan, Georg ^a,c   Pinski, Jacek ^a   Halmos, Gabor ^a   Szepeshazi, Karoly ^a   Cai, Ren Zhi ^a   Groot, Kate ^b   Schally, Andrew V ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c St Johanns Spital   (Austria)

Author keywords

Bombesin antagonist; Cetrorelix; LH RH antagonist; Nude mouse; PC 3 tumor; Peptide antagonists; Prostatic cancer; Xenografts

Indexed keywords

ANDROGEN; BOMBESIN; BOMBESIN ANTAGONIST; BOMBESIN RECEPTOR; CETRORELIX; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GASTRIN RELEASING PEPTIDE; GONADORELIN; MEMBRANE RECEPTOR; RC 39400II; RC 3940II; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOASSAY; RECEPTOR DOWN REGULATION; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BOMBESIN; CELL DIVISION; DNA, NEOPLASM; DRUG COMBINATIONS; GASTRINS; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LUTEINIZING HORMONE; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, BOMBESIN; TESTOSTERONE; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0030751523     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970801)32:3<164::AID-PROS2>3.0.CO;2-L     Document Type: Article

References (50)

1. Wood DP Jr, Banks ER, Humphreys S, McRoberts JW, Rangnekar VM: Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 74:2533-2540, 1994.
2. Garnick MB: Prostate cancer: Screening, diagnosis, and management. Ann Intern Med 118:804-818, 1993.
3. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273:289-295, 1995.
4. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 152:1831-1836, 1994.
5. Schally AV, Comaru-Schally AM, Gonzalez-Barcena D: Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. Biomed Pharmacother 46:465-471, 1992.
6. Chiarodo A: National Cancer Institute roundtable on prostate cancer: Future reseach directions. Cancer Res 51:2498-2505, 1991.
7. Sharifi R, Soloway M, and The Leuprolide Study Group: Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 143:68-71, 1990.
8. Raghavan D: Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs. Semin Oncol 15:371-389, 1988.
9. Kaighn ME, Shankar Narayan K, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16-23, 1979.
10. Pinski J, Reile H, Halmos G, Groot K, Schally AV: Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 59:51-55, 1994.
11. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV: Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 91:7090-7094, 1994.
12. Shirahige Y, Cook CB, Pinski J, Halmos G, Nair R, Schally AV: Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Int J Oncol 5:1031-1035, 1994.
13. Connolly JM, Rose DP: Interaction between epidermal growth factor-mediated autocrine regulation and linoleic acid-stimulated growth of a human prostate cancer cell line. Prostate 20:151-158, 1992.
14. Davies P, Eaton CL: Binding of epidermal growth factor by human normal, hypertrophic and carcinomatous prostate. Prostate 14:123-132, 1989.
15. 1. Cancer Res 51:2780-2785, 1991.
16. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M: Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63:1714-1720, 1989.
17. 4) bombesin by tumor cells. Prostate 25:29-38, 1994.
18. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fishler A, Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer cells. Nature 316:823-826, 1985.
19. Frucht H, Gazdar A, Jensen RT: Human colon cancer cell line NCI-H716 expresses functional bombesin receptors. Proc Am Assoc Cancer Res 32:47, 1991.
20. Qin Y, Ertl T, Cai RZ, Halmos G, Schally AV: Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res 54:1035-1041, 1994.
21. Qin Y, Halmos G, Cai RZ, Szoke B, Ertl T, Schally AV: Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. J Cancer Res Clin Oncol 200:519-528, 1994.
22. Yano T, Pinski J, Groot K, Schally AV: Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 52:4545-4547, 1992.
23. Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T: Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Acta Oncol 33:693-701, 1994.
24. Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally AV: Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer 57:574-580, 1994.
25. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K: Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res 54:5895-5901, 1994.
26. Pinski J, Schally AV, Halmos G, Szepeshazi K: Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int J Cancer 55:963-967, 1993.
27. 2 showing high binding affinity to bombesin/GRP receptors on CFPAC-1 human pancreatic cancer cells. Int J Oncol 6:1165-1172, 1995.
28. Janik P, Briand P, Hartmann NR: The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 35: 3698-3704, 1975.
29. Halmos G, Pinski J, Szoke B, Schally AV: Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Lett 85:111-118, 1994.
30. Szepeshazi K, Schally AV, Halmos G, Groot K, Radulovic S: Antagonist of bombesin/gastrin releasing peptide inhibits growth of estrogen dependent and independent MXT mammary cancers in mice. J Natl Cancer Inst 84:1916-1922, 1992.
31. Munson JP, Rodbard D: A versatile computerized approach for characterization of ligand binding systems. Anal Biochem 107: 220-239, 1980.
32. Chiu KY, Loke SL, Wong KK: Improved silver technique for showing nuclear organiser regions in paraffin wax sections. J Clin Pathol 42:992-994, 1989.
33. Szepeshazi K, Cai RZ, Radulovic S, Milovanovic S, Szoke B, Schally AV: Inhibitory effect of bombesin/GRP antagonist RC-3095 and high dose of somatostatin analog RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res 51: 5980-5986, 1991.
34. Steel RGD, Torrie J: "Principles and Procedures of Statistics." New York: McGraw Hill, 1976.
35. 11] substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small lung cancer cells in vitro. Proc Natl Acad Sci USA 81:1859-1863, 1988.
36. Liebow C, Crean DH, Lee MT, Kamer AR, Mang TS, Schally AV: Synergistic effects of bombesin and epidermal growth factor on cancer. Proc Natl Acad Sci USA 91:3804-3808, 1994.
37. Qin Y, Ertl T, Cai RZ, Horvath JE, Groot K, Schally AV: Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Int J Cancer 63:257-262, 1995.
38. Emons G, Schally AV: The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers. Hum Reprod 9:1364-1379, 1994.
39. Szende B, Srkalovic G, Groot K, Lapis K, Schally AV: Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists and agonists. Cancer Res 50:3716-3721, 1990.
40. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV: Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 21:181-192, 1992.
41. Limonta P, Dondi D, Moretti M, Maggi R, Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75:207-212, 1992.
42. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on the human androgen-independent prostate cancer cell line DU-145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54:4091-4095, 1994.
43. Kakar SS, Grizzle WE, Neill JD: The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in the pituitary. Mol Cell Endocrinol 106: 145-149, 1994.
44. Korkut E, Bokser L, Comaru-Schally AM, Groot K, Schally AV: Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing antagonist SB-75. Proc Natl Acad Sci USA 88:844-848, 1991.
45. Horvath J, Ertl T, Qin Y, Groot K, Schally AV: LH-RH and its antagonist Cetrorelix inhibit growth of JAR human choriocarcinoma cells in vitro. Int J Oncol 6:969-975, 1995.
46. Gonzales-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes-Garzia M, Cardenas-Cornejo I, Graef-Sanchez A, Comaru-Schally AM, Schally AV: Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia (BPH) and prostatic cancer. Prostate 24:84-92, 1994.
47. Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT: Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res 52:2538-2544, 1992.
48. Redding TW, Schally AV: Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists. J Endocrinol 126:309-315, 1990.
49. van Steenbrugge GJ, Ultee-van Gessel AM, Groen M, de Jong FH, Schroeder FH: Administration of an LHRH-antagonist to male mice: Effects on in vivo secretion of hormones and on the growth of a transplantable human prostatic carcinoma. Life Sci 40:1335-1343, 1987.
50. Pinski J, Yano T, Schally AV: Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats. Neuroendocrinology 56:831-837, 1992.